Medtronic’s long struggle to launch its Symplicity Spyral renal denervation (RDN) technology on the US market is not going to get any easier following a mixed review by the US Food and Drug Administration’s circulatory system devices advisory panel.
The panel considered the company's premarket approval application (PMA) for Symplicity Spyral on 23 August, one day after it considered...